Gate2Brain S.L. was founded on July 3, 2020 as a spin-off of the Institute for Biomedical Research of Barcelona (IRB Barcelona), the University of Barcelona (CIC-UB) and the Hospital St. Joan de Déu (HSJD). Gate2Brain's entrepreneurial team is multidisciplinary and consists of 4 professionals of training and complementary experience that guarantees the viability of the business project: Dr. Meritxell Teixidó, Dr. Gloria Sanclimens, Ms. Esther Riambau and Dr. Ángel Montero-Carcaboso.
Gate2Brain exploits the technology developed during the last 15 years that resulted in three families of peptide shuttles with the ability to cross the Blood-Brain Barrier (BBB), a physical wall that hinders the access of most drugs to the brain and makes it extremely complex to reach this organ. The flagship product, G2B-002, is a promising therapy for pediatric brain tumors such as diffuse intrinsic pediatric glioma (DIPG) and pediatric glioblastoma (pGBM), between other pediatric and adult brain tumors with intact BBB, currently without a cure or with poor prognostic, such as adult glioblastoma (aGBM). Our therapy will initiate the first in human (FIH) clinical trials in 2026.
In 2023 we have raised EIC Accelerator Grant-first with a total amount of 2.5M€ and currently we are actively seeking a 5M€ Series A to finish the Regulatory Preclinal and prepare the clinical batch for Clinical Trial approval and IMPD submission.